Orphan Drugs Pricing – Adaptive Pathways & RWE – Unmet Need Definition ISPOR 20th Annual European Congress – 6-8 Nov 2017, Glasgow, UK

By sonia ziouani ammor In Events, Presentations Tagged Adaptive Pathways, ISPOR, Orphan Drugs, P&R, Pricing, RWE, Unmet Need

Orphan Drugs Pricing and Sustainability At a workshop entitled “Sustainable Funding and Fair Pricing for Orphan Drugs: What Are the Solutions?”, the panellists discussed the options that exist to make funding of valuable orphan medicinal products (OMPs) sustainable for healthcare systems while also

Adaptive Pathways, Biosimilars, Rare Diseases – ISPOR 19th Annual European Congress – 29 Oct-2 Nov 2016, Vienna, Austria

By sonia ziouani ammor In Events, Presentations Tagged ADAPT SMART, Adaptive Pathways, biosimilars, EMA, EU, ISPOR, Off-label drug, Patient Access, Rare Diseases

Adaptive Pathways and Patient AccessAn issue panel entitled Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? was held and moderated by Jacoline Bouvy, Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK. Jacoline

Synergies between Regulatory and Health Technology Assessments – ISPOR 19th Annual European Congress – 29 Oct-2 Nov 2016, Vienna, Austria

By sonia ziouani ammor In Events, Presentations Tagged Early dialogue, EMA, EUnetHTA, Europe, HTA, ISPOR, PRIME, regulatory

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) opened last Monday its 19th Annual European Congress in Vienna, Austria with a plenary session entitled What Synergies Could Be Created Between Regulatory and Health Technology Assessments?The plenary discussion was moderated by

Archive